A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects

被引：0
作者：
Jim Bush
Kazuki Kawakami
Rafael Muniz
机构：
[1] Clinical Pharmacology Physicians Covance Clinical Research Unit Limited,Executive Medical Director, Global Head
[2] Manager,undefined
[3] Medical Document Group,undefined
[4] Mylan Inc.,undefined
来源：
BMC Pharmacology and Toxicology | / 20卷
关键词：
Adalimumab; Biosimilar; Immunogenicity; Pharmacokinetics; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 13 条
[1]  
Schiff MH(2006)Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis Ann Rheum Dis 65 889-1415
[2]  
Burmester GR(2017)Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects Br J Clin Pharmacol 83 1405-223
[3]  
Kent JD(2015)Biosimilar vs biological agents in rheumatology: when are biosimilar agents similar enough? Int Immunopharmacol 27 220-e1910
[4]  
Puri A(2016)Statistical primer on biosimilar clinical development Am J Ther 23 e1903-208
[5]  
Niewiarowski A(2016)Biosimilars: a consideration of the regulations in the United States and European Union Regul Toxicol Pharmacol 76 199-undefined
[6]  
Arai Y(undefined)undefined undefined undefined undefined-undefined
[7]  
Lie G(undefined)undefined undefined undefined undefined-undefined
[8]  
Sciascia S(undefined)undefined undefined undefined undefined-undefined
[9]  
Cuadrado MJ(undefined)undefined undefined undefined undefined-undefined
[10]  
Isakov L(undefined)undefined undefined undefined undefined-undefined
12